W

Walvax Biotechnology Co Ltd
SZSE:300142

Watchlist Manager
Walvax Biotechnology Co Ltd
SZSE:300142
Watchlist
Price: 14.46 CNY -5.61% Market Closed
Market Cap: 23.1B CNY
Have any thoughts about
Walvax Biotechnology Co Ltd?
Write Note

Walvax Biotechnology Co Ltd
Operating Expenses

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Walvax Biotechnology Co Ltd
Operating Expenses Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Expenses CAGR 3Y CAGR 5Y CAGR 10Y
W
Walvax Biotechnology Co Ltd
SZSE:300142
Operating Expenses
-ÂĄ2.3B
CAGR 3-Years
-7%
CAGR 5-Years
-28%
CAGR 10-Years
-18%
Beigene Ltd
HKEX:6160
Operating Expenses
-ÂĄ23.5B
CAGR 3-Years
-22%
CAGR 5-Years
-32%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Operating Expenses
-ÂĄ3.1B
CAGR 3-Years
-41%
CAGR 5-Years
-42%
CAGR 10-Years
N/A
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
Operating Expenses
-ÂĄ954.2m
CAGR 3-Years
-6%
CAGR 5-Years
2%
CAGR 10-Years
-19%
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Operating Expenses
-ÂĄ4.6B
CAGR 3-Years
-29%
CAGR 5-Years
-28%
CAGR 10-Years
-30%
Imeik Technology Development Co Ltd
SZSE:300896
Operating Expenses
-ÂĄ649m
CAGR 3-Years
-53%
CAGR 5-Years
-35%
CAGR 10-Years
N/A
No Stocks Found

Walvax Biotechnology Co Ltd
Glance View

Market Cap
23.2B CNY
Industry
Biotechnology

Walvax Biotechnology Co., Ltd. engages in the research and development, production, and sale of biopharmaceutical products. The company is headquartered in Kunming, Yunnan and currently employs 1,866 full-time employees. The company went IPO on 2010-11-12. The Company’s main products include haemophilus influenza type b conjugate vaccines, freeze-dried group A,C meningococcal polysaccharide conjugate vaccines, group ACYW135 meningococcal polysaccharide vaccines and group A and C meningococcal polysaccharide vaccines, among others. The firm distributes its products mainly in domestic market.

Intrinsic Value
15.56 CNY
Undervaluation 7%
Intrinsic Value
Price
W

See Also

What is Walvax Biotechnology Co Ltd's Operating Expenses?
Operating Expenses
-2.3B CNY

Based on the financial report for Jun 30, 2024, Walvax Biotechnology Co Ltd's Operating Expenses amounts to -2.3B CNY.

What is Walvax Biotechnology Co Ltd's Operating Expenses growth rate?
Operating Expenses CAGR 10Y
-18%

Over the last year, the Operating Expenses growth was 25%. The average annual Operating Expenses growth rates for Walvax Biotechnology Co Ltd have been -7% over the past three years , -28% over the past five years , and -18% over the past ten years .

Back to Top